NASDAQ : NERV

Minerva Neurosciences, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 2.05 USD (Oct 30, 2026, 3:16 PM EDT) · Market cap 97.88M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Details

NameMinerva Neurosciences, Inc.
SectorHealthcare
IndustryBiotechnology
Employees7
Founded2007
Ipo Date2014-07-01
CeoRemy Luthringer
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS6033802058
Cusip603380205
Cik0001598646
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Remy Luthringer Ph.D.Executive Chairman, Chief Executive Officer and Member of Scientific Advisory Board
Frederick W. Ahlholm CPASenior Vice President, Chief Financial Officer and Secretary
Joseph ReillySenior Vice President and Chief Operating Officer
Anthony AliquoChief Accounting Officer and Principal Accounting Officer
William B. BoniVice President of Investor Relations and Corporate Communications
James O'ConnorChief Business Officer and General Counsel
Prof. Michael Davidson M.D.Member of Scientific Advisory Board and Chief Medical Officer

Contact

Address1500 District Avenue, Burlington, Massachusetts 01803, United States
Phone617 600 7373
Websitehttps://www.minervaneurosciences.com